Sangamo Therapeutics (NASDAQ: SGMO) reported Q3 EPS of ($0.13), $0.13 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $23.6 million versus the consensus estimate of $26.96 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.